Objective:To explore the possible mechanism of Soufeng Qutan traditional Chinese medicine in the treatment of atherosclerosis.Methods:Mice of six weeks old which were knocked out gene ApoE and fed with a high-fat diet...Objective:To explore the possible mechanism of Soufeng Qutan traditional Chinese medicine in the treatment of atherosclerosis.Methods:Mice of six weeks old which were knocked out gene ApoE and fed with a high-fat diet for 13 weeks to establish a model of atherosclerotic unstable plaque,and they were randomly divided into the model group,the atorvastatin group and the low,medium,and high-dose Shoufeng Qutan groups.In addition,six weeks old C57BL/6J mice were set as the blank con?trol group. Both the blank control group and the model group were given 0.9% normal saline by gavage. The low,medium,and high-dose groups of Soufeng Qutangroup and the atorvastatin group were given different doses of Soufeng Qutan Chinese Medicine Decoction and atorvastatin. After 13 weeks,the mice were sacrificed,and the abdominal aortic blood vessels were observed by HE staining. Total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C). and high-density lipopro?tein cholesterol(HDL-C)content were detected by a biochemical automatic analyzer and IL-1β levels were detected by ELISA.Results:Compared with the blank control group,a large number of foam cells could be seen in the model group with obvious plaques;serum TC,TG,LDL-C,and IL-1β levels were significantly increased(P<0.05),and HDL-C level was markedly de?creased (P<0.05). Compared with the model group,the Soufeng Qutangroup at all doses and the atorvastatin group had a small amount of foam cells and reduced plaque area;serum TC,TG,LDL-C,and IL-1β levels were significantly decreased (P<0.05),and the level of HDL-C was significantly increased (P<0.05).Conclusion:Soufeng Qutan Chinesemedicine can inhibit the pro?gression of cellular inflammation,downregulate the expression of IL-1β,reduce plaques,and improve blood lipids. This may be one of the molecular mechanisms of Soufeng Qutan Chinese medicine in the early treatment of atherosclerosis.展开更多
Background:Hypertension,a prevalent disease,is a significant risk factor for coronary heart disease.Huoxue Qianyang Qutan Recipe (HQQR),a traditional Chinese herbal remedy,has been used for treating hypertension over ...Background:Hypertension,a prevalent disease,is a significant risk factor for coronary heart disease.Huoxue Qianyang Qutan Recipe (HQQR),a traditional Chinese herbal remedy,has been used for treating hypertension over several years.Objective:This study assesses HQQR’s efficacy for controlling blood pressure among patients with hypertension related to blood stasis,yang hyperactivity and phlegm.Design,setting,participants and interventions:A randomized controlled trial was conducted at the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine,China,from July 2020 to June 2022.Major components of HQQR were identified using thin-layer chromatography and high-performance liquid chromatography.Participants aged18–80 years,exhibiting traditional Chinese medicine syndromes of blood stasis,yang hyperactivity or phlegm,along with grades 1 or 2 hypertension,were randomly categorized into two groups.The intervention group was given HQQR granules alongside conventional hypertension treatment,while the control group was given placebo granules in addition to conventional treatment for 12 weeks.Main outcome measures:The primary outcome was clinic blood pressure,whereas secondary outcomes included metabolic indices (e.g.,homeostasis model assessment of insulin resistance[HOMA-IR],total cholesterol[TC],low-density lipoprotein cholesterol and triglyceride),target organ damage indices (left ventricular mass index and urinary albumin creatinine ratio[UACR]) and inflammation indices(interleukin-6[IL-6]and high-sensitivity C-reactive protein[hs-CRP]).Results:HQQR’s primary components were identified as salvianolic acid B,emodin and ferulic acid.Of the 216 participants (108 in each group),compared to the control,the intervention group exhibited significant improvements (P<0.001) in clinic systolic blood pressure ([136.24±7.63]vs[130.06±8.50]mmHg),clinic diastolic blood pressure ([84.34±8.72]vs[80.46±6.05]mmHg),home systolic blood pressure([131.64±8.74]vs[122.36±8.45]mmHg) and home diastolic blood pressure ([78.47±9.53]vs[71.79±6.82]mm Hg).HQQR demonstrated a reduction in ambulatory blood pressure (24-hour systolic blood pressure:[133.75±10.49]vs[132.46±8.84]mmHg and 24-hour diastolic blood pressure:[84.12±8.01]vs[82.11±7.45]mmHg) and an improvement in HOMA-IR ([4.09±1.72]vs[3.98±1.44]),TC ([4.66±1.47]vs[3.75±1.81]mmol/L) and UACR (75.94[5.12,401.12]vs 45.61[4.26,234.26]).Moreover,HQQR demonstrated a decrease in hs-CRP (1.46[0.10,10.53]vs 0.57[0.12,3.99]mg/L) and IL-6 (6.69[2.00,29.74]vs 5.27[2.00,9.73]pg/mL),with no reported side effects (P<0.001).Conclusion:This study highlights the therapeutic potential of HQQR use in ameliorating blood pressure,glycolipid metabolism,and inflammation in patients with hypertension.展开更多
OBJECTIVE:To investiage the possible mechanism underlying the effect of the Jianpi Qutan Fang(健脾祛痰方,JPQT)on Atherosclerosis(AS)which is the main pathological process of most cardiovascular diseases that affect mi...OBJECTIVE:To investiage the possible mechanism underlying the effect of the Jianpi Qutan Fang(健脾祛痰方,JPQT)on Atherosclerosis(AS)which is the main pathological process of most cardiovascular diseases that affect millions of adults worldwide.METHODS:In the present study,rats were fed with a high-fat-diet(HFD)with vitamin D3 for 16 weeks and were orally administered atorvastatin treatment and different doses of JPQT.Histopathological changes and ultrastructural changes in the aorta were evaluated through hematoxylin-eosin staining and transmission electron microscopy(TEM),respectively.Suppressor of cytokine signaling 1(SOCS1)/Janus kinase 1(JAK1)/signal transducer and activator of transcription 1(STAT1)signaling pathways were detected through Western blotting.RESULTS:JPQT treatment decreased the lipid levels of triglyceride,low-density lipoprotein,and cholesterol,the inflammatory cytokine levels of interleukin 1 beta(IL-1β),IL-6 and IL-8 in rat serum,but increased high-density lipoprotein and IL-10 serum levels.JPQT treatment ameliorated pathological changes in the aorta of AS model rats.Moreover,JPQT upregulated SOCS1 protein expression and down-regulated phosphorylated protein expression levels of p-JAK1 and p-STAT1.CONCLUSION:These results suggest that JPQT induces anti-atherosclerosis effects through anti-inflammatory and inhibiting JAK/STAT signaling pathways in HFD fed rats.展开更多
目的基于CYP2J3/EETs介导脂肪酸代谢探讨化瘀祛痰方防治血脂异常的机制。方法32只SPF级SD大鼠分为空白对照组、模型组、化瘀祛痰方组、辛伐他汀组,每组8只。除空白对照组外,其他各组给予高脂饲料喂饲,建立高脂血症模型。于第13周开始,...目的基于CYP2J3/EETs介导脂肪酸代谢探讨化瘀祛痰方防治血脂异常的机制。方法32只SPF级SD大鼠分为空白对照组、模型组、化瘀祛痰方组、辛伐他汀组,每组8只。除空白对照组外,其他各组给予高脂饲料喂饲,建立高脂血症模型。于第13周开始,化瘀祛痰方组给予化瘀祛痰方灌胃,辛伐他汀组给予辛伐他汀灌胃,空白对照组、模型组给予相应体积的生理盐水灌胃,每日1次,灌胃4周。采用全自动生化分析仪检测各组大鼠血清中总胆固醇(Total cholesterol,TC)、甘油三酯(Triglyceride,TG)、低密度脂蛋白胆固醇(Low density lipoprotein cholesterol,LDL-C)及高密度脂蛋白胆固醇(High density lipoprotein cholesterol,HDL-C)水平;HE染色观察肝脏组织病理变化;Elisa检测各组大鼠肝脏14,15-环氧二十碳三烯酸(14,15-epoxyeicosatrienoic acid,14,15-EET)水平;Real time RT-PCR检测肝脏组织细胞色素P450表氧化酶2J3(Cytochrome P450 oxidase 2J3,CYP2J3)、肉毒碱棕榈酰转移酶1(Carnitine palmitoyltransferase-1,CPT-1)mRNA水平;Western blot法检测肝脏组织CYP2J3、腺苷酸活化蛋白激酶(AMP-actived protein kinase,AMPK)、磷酸化腺苷酸活化蛋白激酶(p-AMPK)、乙酰辅酶A羧化酶(Acetyl CoA Carboxylase,ACC)、磷酸化乙酰辅酶A羧化酶(p-ACC)、CPT-1蛋白水平。结果与空白对照组比较,模型组大鼠血清TC、TG和LDL-C水平显著升高(P<0.01),HDL-C水平显著降低(P<0.05);肝脏脂质沉积显著,可见大量脂滴;肝脏组织内14,15-EET含量显著降低(P<0.01);肝脏CYP2J3、CPT-1 mRNA和蛋白表达水平显著降低(P<0.01),p-AMPK/AMPK、p-ACC/ACC显著降低(P<0.01)。与模型组比较,经化瘀祛痰方及辛伐他汀干预后,大鼠血清TC、TG和LDL-C水平显著降低(P<0.05或P<0.01),HDL-C水平显著升高(P<0.05);肝脏脂质沉积情况明显改善,脂滴数明显减少;肝脏组织内14,15-EET水平显著升高(P<0.01);肝脏CYP2J3、CPT-1 mRNA和蛋白表达水平显著升高(P<0.05或P<0.01),p-AMPK/AMPK、p-ACC/ACC显著升高(P<0.05或P<0.01)。结论化瘀祛痰方可有效改善高脂血症大鼠血脂异常,减轻肝脏脂质沉积情况,其机制可能与CYP2J3/EETs介导脂肪酸代谢密切相关。展开更多
基金Distinguished Professor Project of Liaoning Province([2018]No.35)。
文摘Objective:To explore the possible mechanism of Soufeng Qutan traditional Chinese medicine in the treatment of atherosclerosis.Methods:Mice of six weeks old which were knocked out gene ApoE and fed with a high-fat diet for 13 weeks to establish a model of atherosclerotic unstable plaque,and they were randomly divided into the model group,the atorvastatin group and the low,medium,and high-dose Shoufeng Qutan groups.In addition,six weeks old C57BL/6J mice were set as the blank con?trol group. Both the blank control group and the model group were given 0.9% normal saline by gavage. The low,medium,and high-dose groups of Soufeng Qutangroup and the atorvastatin group were given different doses of Soufeng Qutan Chinese Medicine Decoction and atorvastatin. After 13 weeks,the mice were sacrificed,and the abdominal aortic blood vessels were observed by HE staining. Total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C). and high-density lipopro?tein cholesterol(HDL-C)content were detected by a biochemical automatic analyzer and IL-1β levels were detected by ELISA.Results:Compared with the blank control group,a large number of foam cells could be seen in the model group with obvious plaques;serum TC,TG,LDL-C,and IL-1β levels were significantly increased(P<0.05),and HDL-C level was markedly de?creased (P<0.05). Compared with the model group,the Soufeng Qutangroup at all doses and the atorvastatin group had a small amount of foam cells and reduced plaque area;serum TC,TG,LDL-C,and IL-1β levels were significantly decreased (P<0.05),and the level of HDL-C was significantly increased (P<0.05).Conclusion:Soufeng Qutan Chinesemedicine can inhibit the pro?gression of cellular inflammation,downregulate the expression of IL-1β,reduce plaques,and improve blood lipids. This may be one of the molecular mechanisms of Soufeng Qutan Chinese medicine in the early treatment of atherosclerosis.
基金funded by the Program of Shanghai Municipal Health Commission (No.19401970400)the National Natural Science Foundation of China (No.82174130 and No.82274262)Shanghai Collaborative Innovation Center of Industrial Transformation of Hospital TCM Preparation。
文摘Background:Hypertension,a prevalent disease,is a significant risk factor for coronary heart disease.Huoxue Qianyang Qutan Recipe (HQQR),a traditional Chinese herbal remedy,has been used for treating hypertension over several years.Objective:This study assesses HQQR’s efficacy for controlling blood pressure among patients with hypertension related to blood stasis,yang hyperactivity and phlegm.Design,setting,participants and interventions:A randomized controlled trial was conducted at the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine,China,from July 2020 to June 2022.Major components of HQQR were identified using thin-layer chromatography and high-performance liquid chromatography.Participants aged18–80 years,exhibiting traditional Chinese medicine syndromes of blood stasis,yang hyperactivity or phlegm,along with grades 1 or 2 hypertension,were randomly categorized into two groups.The intervention group was given HQQR granules alongside conventional hypertension treatment,while the control group was given placebo granules in addition to conventional treatment for 12 weeks.Main outcome measures:The primary outcome was clinic blood pressure,whereas secondary outcomes included metabolic indices (e.g.,homeostasis model assessment of insulin resistance[HOMA-IR],total cholesterol[TC],low-density lipoprotein cholesterol and triglyceride),target organ damage indices (left ventricular mass index and urinary albumin creatinine ratio[UACR]) and inflammation indices(interleukin-6[IL-6]and high-sensitivity C-reactive protein[hs-CRP]).Results:HQQR’s primary components were identified as salvianolic acid B,emodin and ferulic acid.Of the 216 participants (108 in each group),compared to the control,the intervention group exhibited significant improvements (P<0.001) in clinic systolic blood pressure ([136.24±7.63]vs[130.06±8.50]mmHg),clinic diastolic blood pressure ([84.34±8.72]vs[80.46±6.05]mmHg),home systolic blood pressure([131.64±8.74]vs[122.36±8.45]mmHg) and home diastolic blood pressure ([78.47±9.53]vs[71.79±6.82]mm Hg).HQQR demonstrated a reduction in ambulatory blood pressure (24-hour systolic blood pressure:[133.75±10.49]vs[132.46±8.84]mmHg and 24-hour diastolic blood pressure:[84.12±8.01]vs[82.11±7.45]mmHg) and an improvement in HOMA-IR ([4.09±1.72]vs[3.98±1.44]),TC ([4.66±1.47]vs[3.75±1.81]mmol/L) and UACR (75.94[5.12,401.12]vs 45.61[4.26,234.26]).Moreover,HQQR demonstrated a decrease in hs-CRP (1.46[0.10,10.53]vs 0.57[0.12,3.99]mg/L) and IL-6 (6.69[2.00,29.74]vs 5.27[2.00,9.73]pg/mL),with no reported side effects (P<0.001).Conclusion:This study highlights the therapeutic potential of HQQR use in ameliorating blood pressure,glycolipid metabolism,and inflammation in patients with hypertension.
基金the National Natural Science Foundation of China:Explore the Regulatory Mechanism of Coronary Endothelial Immune Inflammation Mediated by Micro RNA155-SOCS1 Axis in Bama Pigs based on “Xin Shou Qi Yu Pi”(No.81703970)the National 973 Program on Key Basic Research Project:Study on the Therapeutic Mechanism and Rule of Treating Angina Pectoris based on “Cong Pi Lun Zhi”(No.2013CB531704)
文摘OBJECTIVE:To investiage the possible mechanism underlying the effect of the Jianpi Qutan Fang(健脾祛痰方,JPQT)on Atherosclerosis(AS)which is the main pathological process of most cardiovascular diseases that affect millions of adults worldwide.METHODS:In the present study,rats were fed with a high-fat-diet(HFD)with vitamin D3 for 16 weeks and were orally administered atorvastatin treatment and different doses of JPQT.Histopathological changes and ultrastructural changes in the aorta were evaluated through hematoxylin-eosin staining and transmission electron microscopy(TEM),respectively.Suppressor of cytokine signaling 1(SOCS1)/Janus kinase 1(JAK1)/signal transducer and activator of transcription 1(STAT1)signaling pathways were detected through Western blotting.RESULTS:JPQT treatment decreased the lipid levels of triglyceride,low-density lipoprotein,and cholesterol,the inflammatory cytokine levels of interleukin 1 beta(IL-1β),IL-6 and IL-8 in rat serum,but increased high-density lipoprotein and IL-10 serum levels.JPQT treatment ameliorated pathological changes in the aorta of AS model rats.Moreover,JPQT upregulated SOCS1 protein expression and down-regulated phosphorylated protein expression levels of p-JAK1 and p-STAT1.CONCLUSION:These results suggest that JPQT induces anti-atherosclerosis effects through anti-inflammatory and inhibiting JAK/STAT signaling pathways in HFD fed rats.
文摘目的基于CYP2J3/EETs介导脂肪酸代谢探讨化瘀祛痰方防治血脂异常的机制。方法32只SPF级SD大鼠分为空白对照组、模型组、化瘀祛痰方组、辛伐他汀组,每组8只。除空白对照组外,其他各组给予高脂饲料喂饲,建立高脂血症模型。于第13周开始,化瘀祛痰方组给予化瘀祛痰方灌胃,辛伐他汀组给予辛伐他汀灌胃,空白对照组、模型组给予相应体积的生理盐水灌胃,每日1次,灌胃4周。采用全自动生化分析仪检测各组大鼠血清中总胆固醇(Total cholesterol,TC)、甘油三酯(Triglyceride,TG)、低密度脂蛋白胆固醇(Low density lipoprotein cholesterol,LDL-C)及高密度脂蛋白胆固醇(High density lipoprotein cholesterol,HDL-C)水平;HE染色观察肝脏组织病理变化;Elisa检测各组大鼠肝脏14,15-环氧二十碳三烯酸(14,15-epoxyeicosatrienoic acid,14,15-EET)水平;Real time RT-PCR检测肝脏组织细胞色素P450表氧化酶2J3(Cytochrome P450 oxidase 2J3,CYP2J3)、肉毒碱棕榈酰转移酶1(Carnitine palmitoyltransferase-1,CPT-1)mRNA水平;Western blot法检测肝脏组织CYP2J3、腺苷酸活化蛋白激酶(AMP-actived protein kinase,AMPK)、磷酸化腺苷酸活化蛋白激酶(p-AMPK)、乙酰辅酶A羧化酶(Acetyl CoA Carboxylase,ACC)、磷酸化乙酰辅酶A羧化酶(p-ACC)、CPT-1蛋白水平。结果与空白对照组比较,模型组大鼠血清TC、TG和LDL-C水平显著升高(P<0.01),HDL-C水平显著降低(P<0.05);肝脏脂质沉积显著,可见大量脂滴;肝脏组织内14,15-EET含量显著降低(P<0.01);肝脏CYP2J3、CPT-1 mRNA和蛋白表达水平显著降低(P<0.01),p-AMPK/AMPK、p-ACC/ACC显著降低(P<0.01)。与模型组比较,经化瘀祛痰方及辛伐他汀干预后,大鼠血清TC、TG和LDL-C水平显著降低(P<0.05或P<0.01),HDL-C水平显著升高(P<0.05);肝脏脂质沉积情况明显改善,脂滴数明显减少;肝脏组织内14,15-EET水平显著升高(P<0.01);肝脏CYP2J3、CPT-1 mRNA和蛋白表达水平显著升高(P<0.05或P<0.01),p-AMPK/AMPK、p-ACC/ACC显著升高(P<0.05或P<0.01)。结论化瘀祛痰方可有效改善高脂血症大鼠血脂异常,减轻肝脏脂质沉积情况,其机制可能与CYP2J3/EETs介导脂肪酸代谢密切相关。
